Hodgkin's disease. Combined clinical staff conference at the National Institutes of Health.
D002699:Chlorambucil / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004357:Drug Synergism; D006689:Hodgkin Disease / Q000145:classification* / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology* / Q000473:pathology* / Q000532:radiotherapy*; D006801:Humans; D006968:Hypersensitivity, Delayed; D007275:Injections, Intravenous; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D014747:Vinblastine / Q000627:therapeutic use*
D009588:Nitrogen Mustard Compounds; D002699:Chlorambucil; D014747:Vinblastine; D003520:Cyclophosphamide; D011241:Prednisone